HomeAI · summaries
Storia in 4 fonti
Alnylam shares tank 29% as Amvuttra disappoints with ATTR outlook cut for 2026
Alnylam Pharmaceuticals’ stock price plummeted as much as 29% Thursday morning after disappointing Amvuttra sales and a lowered full-y | Alnylam’s stock price plummeted as much as 29% Thursday morning after disappointing Amvuttra sales and a lowered full-year forecast triggered fresh concerns over the ATTR franchise.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
Alnylam's stock is down 30% despite a booming biotech market. Here's why.
Alnylam's stock is down 30% in 2026 despite Amvuttra's success. Wainua's Phase 3 failure raised doubts about RNAi silencers like Amvuttra and nucresiran. Q2 earnings due July 30.
- ·
fiercepharma.com
Teva’s innovation engine offsets generics slump, leaving one analyst ‘shocked’ by Ajovy’s surge
As Teva proceeds down the more muted growth path that it telegraphed early this year, the generics and innovative medicines hybrid isn’t letting a little sales slump affect its…
